[Federal Register Volume 75, Number 141 (Friday, July 23, 2010)]
[Notices]
[Pages 43190-43193]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-17794]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Statement of Organization, Functions, and Delegations of 
Authority

    Part C (Centers for Disease Control and Prevention) of the 
Statement of Organization, Functions, and Delegations of Authority of 
the Department of Health and Human Services (45 FR 67772-76, dated 
October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as 
amended most recently at 75 FR 34465, dated June 9, 2010) is amended to 
reflect the substructure of the National Center for Emerging and 
Zoonotic Infectious Diseases, Office of Infectious Diseases, Centers 
for Disease Control and Prevention.
    Section C-B, Organization and Functions, is hereby amended as 
follows:

    After the title and functional statements for the National 
Center for Immunization and Respiratory Diseases (CVG), insert the 
following:
    National Center for Emerging and Zoonotic Infectious Diseases 
(CVL). The National Center for Emerging and Zoonotic Infectious 
Diseases (NCEZID) works to prevent and control a broad range of 
infectious diseases through public leadership, partnerships, 
science, and systems. In carrying out these activities, NCEZID: (1) 
Works collaboratively across CDC and with external partners to 
conduct, coordinate, support, and evaluate public health efforts to 
prevent and minimize morbidity and mortality due to infectious 
diseases, promoting a One Health approach involving the interface of 
animal, human, and environmental factors; (2) develops, evaluates, 
and advances science, programs, management, and operations toward 
meeting the agency's infectious disease related mission and goals; 
(3) conducts epidemiologic and laboratory science and applied 
research aimed at identifying risk factors and disease burdens and 
developing and implementing public health programs, practices, and 
policies for infectious disease prevention and control; (4) works 
with domestic and global partners to provide technical and subject 
matter expertise in responding to outbreaks and in establishing, 
maintaining, and evaluating disease control and prevention programs; 
(5) supports a broad range of cross-cutting and collaborative 
programs aimed at enhancing public health capacity at the local, 
State, and national levels; (6) works to improve the quality and 
safety of healthcare through efforts to reduce healthcare associated 
infections and antimicrobial resistance and to ensure the safety of 
medical products, including vaccines; (7) conducts activities to 
improve the safety of food and water and reduce related enteric 
illnesses; (8) administers a national quarantine program to prevent 
U.S. importation and spread of infectious diseases; (9) works with 
CDC colleagues and external partners to improve public health 
preparedness at the local, State, and national levels; and (10) 
works to increase public health prevention efforts for populations 
at increased risk for infectious diseases.
    Office of the Director (CVL1). (1) Provides leadership in 
developing, prioritizing, advancing, and evaluating the center's 
science, programs, management, and operations toward meeting agency 
mission and goals; (2) advises the CDC Director and Deputy Director 
for Infectious Diseases on priority issues affecting the center; (3) 
identifies and facilitates synergies within NCEZID, across CDC, and 
with external partners for addressing emerging and zoonotic 
infectious diseases domestically and globally; (4) enhances 
collaborations and partnerships across multiple disciplines, 
including human and animal health; (5) ensures scientific quality 
and ethical and regulatory compliance of center activities; (6) 
provides leadership, guidance, and technical assistance on policy 
and communication issues affecting the center; (7) serves as liaison 
with CDC counterparts, CDC/OD, other government agencies, and 
external partners on policy, program, legislative, communication, 
and budgetary issues related to NCEZID; (8) recruits and supports a 
strong center-wide workforce and builds leadership at the division 
and branch levels; (9) ensures that programmatic goals are achieved 
with measurable impact; and (10) ensures effective administrative 
services for NCEZID as well as effective cross-cutting scientific 
and program services for all CDC's infectious disease national 
centers.
    Food Safety Office (CVL12). (1) Provides leadership in 
preventing and controlling foodborne illness by coordinating related 
activities within CDC and with other local, State, Federal, and 
international organizations; (2) directs the activities related to 
development of long-term NCEZID, OID, and CDC strategies, policies, 
and budgets for foodborne disease prevention activities; (3) 
allocates and tracks interagency resources within CDC for foodborne 
disease surveillance, outbreak response, applied research, education 
and training; (4) administers and tracks resources for foodborne 
disease prevention and control activities of State and local health 
departments and other organizations; (5) represents NCEZID and CDC 
programs and prevention policies in meetings with governmental, non-
governmental, private, and international organizations; (6) reviews, 
prepares, and coordinates congressional testimony and briefing 
documents related to foodborne diseases, and analyzes programmatic 
and policy implications of legislative proposals; and (7) provides 
direction and administrative support to the World Health 
Organization (WHO) Collaborating Center for Foodborne Disease 
Surveillance.
    Division of Foodborne, Waterborne, and Environmental Diseases 
(CVLB). The mission of the Division of Foodborne, Waterborne, and 
Environmental Diseases (DFWED) is to improve public health 
nationally and internationally through the prevention and control of 
disease, disability, and death caused by foodborne, waterborne, and 
environmentally-transmitted infections. In carrying out its mission, 
DFWED: (1) Conducts surveillance, investigations, and studies of 
foodborne bacterial diseases, waterborne bacterial and parasitic 
diseases, and mycotic diseases to define disease etiology and 
develop effective methods for diagnosis, prevention, and control; 
(2) conducts or participates in clinical, field, and laboratory 
research to develop, evaluate, and improve laboratory methodologies, 
materials, and therapeutic practices used for environmental 
detection, diagnosis, treatment, investigation, and control of 
foodborne bacterial diseases, waterborne bacterial and parasitic 
diseases, and mycotic diseases; (3) fosters and coordinates 
environmental microbiology research activities at CDC through the 
Environmental Microbiology Workgroup, partnerships, and advocacy 
activities to promote research on preventing infectious disease 
transmission from the environment to humans; (4) provides epidemic 
aid and epidemiologic consultation, upon request, to State and local 
health departments, other Federal agencies, and national and 
international health organizations; (5) provides reference/
diagnostic services for foodborne bacterial diseases, waterborne 
bacterial and parasitic diseases, and mycotic diseases to State and 
local health departments, other Federal agencies, and national and 
international health organizations; (6) provides scientific and 
technical assistance to other CDC components when the work requires 
unique expertise or specialized equipment not available in other 
components; (7) provides intramural and extramural technical 
expertise and assistance in professional training and proficiency 
testing activities; (8) serves as appropriately designated national 
and international reference centers for various foodborne bacterial 
diseases, waterborne bacterial and parasitic diseases, and mycotic 
diseases and disease groups; and (9) develops clear health promotion 
strategies, campaigns, and messages to promote prevention.
    Office of the Director (CVLB1). (1) Directs and manages the 
programs and activities of DFWED; (2) provides leadership and 
guidance on policy, program planning and development, program 
management, and operations; (3) coordinates or assures coordination 
with the appropriate CDC and

[[Page 43191]]

NCEZID offices on administrative and program matters; (4) reviews, 
prepares, and coordinates congressional testimony and briefing 
documents related to foodborne bacterial diseases, waterborne 
bacterial and parasitic diseases, and mycotic diseases, and analyzes 
programmatic and policy implications of legislative proposals; (5) 
represents CDC and NCEZID programs and prevention policies in 
meetings with governmental, private, and international 
organizations; (6) advises CDC and NCEZID on policy matters 
concerning DFWED programs and activities; (7) provides statistical 
methodology and participates in the DFWED's outbreak investigations 
and disease reporting systems for ongoing surveillance; (8) develops 
new methods or adapts existing methods for statistical applications 
in epidemiologic or laboratory research studies for the division; 
(9) provides statistical consultation for epidemiologic and 
laboratory research studies conducted by the division; (10) assists 
researchers with statistical aspects of report writing and prepares 
statistical portions of papers, protocols, and reports written by 
staff of the division, and trains division professional staff in 
statistical methods; (11) provides oversight for CDC involvement in 
the WHO Global Foodborne Infections Network and training in food, 
water, and zoonotic infection control and prevention; and (12) 
provides subject matter expertise on environmental research, and 
promotes and coordinates related research activities at CDC and with 
collaborative partners.
    Division of Global Migration and Quarantine (CVLC). (1) 
Administers a national quarantine program to protect the U.S. 
against the introduction of diseases from foreign countries and the 
transmission of communicable disease between states; (2) administers 
an overseas program for the medical examination of immigrants, 
refugees, and as necessary, other migrant populations destined for 
legal entry to the U.S., with inadmissible health conditions that 
would pose a threat to public health and impose a burden on public 
health and hospital facilities; (3) conducts surveillance, research, 
and prevention programs to prevent minimize morbidity and mortality 
among the globally mobile populations entering and leaving the U.S.; 
(4) maintains liaison with other Federal agencies, State and local 
health departments, and other stake holders, and provides 
information on global migration and quarantine matters to them; (5) 
provides liaison with international health organizations and 
participates in the development of international agreements 
affecting quarantine; (6) evaluates and provides technical support 
on the development and enforcement of policies necessary for 
implementation of Federal quarantine authority; (7) conducts studies 
to provide new information about health hazards abroad, measures for 
their prevention, and the potential threat of disease introduction 
into the U.S.; and (8) provides logistic support to other programs 
of the CDC in the distribution of requested biological agents and 
movement of biological specimens through U.S. ports of entry.
    Office of the Director (CVLC1). (1) Manages, directs, and 
coordinates the activities of the division; (2) provides leadership 
in development of division policy, program planning, implementation, 
and evaluation; (3) identifies needs and resources for new 
initiatives and assigns responsibilities for their development; (4) 
coordinates liaison with other Federal agencies, State and local 
health departments, and interested industries; (5) coordinates 
liaison with international health organizations; and (6) reviews and 
evaluates all administrative services for both headquarters and 
quarantine stations and provides policy procedures and guidance on 
such matters.
    Division of Healthcare Quality Promotion (CVLD). The mission of 
the Division of Healthcare Quality Promotion (DHQP) is to protect 
patients; protect healthcare personnel; and promote safety, quality, 
and value in both national and international healthcare delivery 
systems. In carrying out its mission, DHQP: (1) Measures, validates, 
interprets, and responds to data relevant to healthcare processes 
and outcomes, healthcare-associated infections, antimicrobial 
resistance, adverse drug events, and other related adverse events or 
medical errors in healthcare affecting patients and healthcare 
personnel; (2) investigates and responds to emerging infections and 
related adverse events among patients and healthcare providers, or 
others associated with the healthcare environment; (3) collaborates 
with academic and public health partners to design, develop, and 
evaluate the efficacy of interventions for preventing infections and 
reducing antimicrobial resistance, and related adverse events or 
medical errors; (4) develops and disseminates evidence-based 
guidelines and recommendations to prevent and control healthcare-
associated infections/antimicrobial resistance, and related adverse 
events or medical errors; (5) promotes the nationwide implementation 
of Healthcare Infection Control Practices Advisory Committee 
(HICPAC) recommendations and other evidence based interventions to 
prevent healthcare-associated infections, antimicrobial resistance, 
and related adverse events or medical errors among patients and 
healthcare personnel; evaluates the impact of these recommendations 
and interventions across the spectrum of healthcare delivery sites; 
(6) monitors vaccine safety and conducts scientific research to 
evaluate the safety of all currently available and new vaccines; (7) 
develops, implements, and evaluates the effectiveness and impact of 
interventions to prevent transmission of healthcare-associated human 
immunodeficiency virus (HIV) and other bloodborne pathogen 
infections; (8) develops and evaluates diagnostic instruments and 
novel laboratory tests to detect and characterize antimicrobial-
resistant bacterial pathogens and the infections that they cause; 
(9) promotes high standards of water quality in healthcare settings 
and tests and assures the water quality for CDC's infectious disease 
laboratories; (10) conducts epidemiologic, and basic and applied 
laboratory research to identify new strategies to prevent 
infections/antimicrobial resistance, and related adverse events or 
medical errors, especially those associated with medical or surgical 
procedures, indwelling medical devices, contaminated products, 
dialysis, and water; (11) establishes evidence-base for surface 
decontamination by performing laboratory research on methods for 
surface sampling detection of selected organisms related to 
preventing healthcare associated infections; (12) serves as the 
National Reference Laboratory for the identification and 
antimicrobial susceptibility testing of staphylococci, anaerobic 
bacteria, non-tuberculous mycobacterial, and those gram-negative 
bacilli causing healthcare associated infections; (13) develops and 
maintains the National Healthcare Safety Network (NHSN), a tool for 
monitoring healthcare-associated infections, measuring healthcare 
outcomes and processes, and monitoring healthcare worker vaccination 
and selected health measures in healthcare facilities; (14) 
continually assesses rates of infections caused by resistant-
bacteria in the U.S. through active surveillance, review of national 
healthcare data sets, and laboratory surveillance programs; (15) 
promotes the integration of the healthcare delivery system in 
Federal/State/local public health preparedness planning; (16) 
coordinates activities, guidance, and research related to infection 
control across the agency and with national and international 
partners; (17) collaborates with other CDC Centers/Institute/Offices 
(CIO) and partners to assure quality clinical microbiology 
laboratory practices through proficiency testing, educational 
programs, and training of personnel; (18) trains Epidemic 
Intelligence Service Officers and other trainees; (19) coordinates 
antimicrobial resistance activities at CDC; (20) works in a national 
leadership capacity with public and private organizations to enhance 
antimicrobial resistance prevention and control, surveillance and 
response, and applied research; and (21) coordinates blood, organ, 
and other tissue safety at CDC.
    Office of the Director (CVLD1). (1) Manages, directs, and 
coordinates the activities of the DHQP; (2) provides leadership and 
guidance on policy, communications/media, program planning and 
development, program management, and operations; (3) provides DHQP-
wide administrative and program services and coordinates or ensures 
coordination with the appropriate CIOs and CDC staff offices on 
administrative and program matters; (4) provides liaison with other 
governmental agencies, international organizations, and other 
outside groups; (5) coordinates, in collaboration with the 
appropriate CIO and CDC components, global health activities 
relating to the prevention of healthcare-associated infections/
antimicrobial resistance, and related adverse events or medical 
errors; (6) coordinates activities, guidance, emergency response, 
and research related to infection control in healthcare settings 
across the agency and with national and international partners; (7) 
works with other Federal agencies, State governments, medical 
societies, and other public and private organizations to promote 
collaboration and to integrate healthcare preparedness in Federal/
State/local public

[[Page 43192]]

health preparedness planning; (8) oversees the coordination of 
antimicrobial resistance activities at CDC; (9) represents CDC as 
co-chair of the Federal Interagency Task Force on Antimicrobial 
Resistance; (10) coordinates with other agencies, State governments, 
medical societies, and other public and private organizations to 
enhance antimicrobial resistance prevention and control, 
surveillance and response, and applied research; (11) leads CDC's 
activities on blood, organ, and other tissue safety; (12) represents 
CDC on the Advisory Committee on Blood Safety and Availability and 
the Advisory Committee on Organ Transplantation; (13) works with 
other Federal agencies, State governments, and other public and 
private organizations to enhance blood, organ, and other tissue 
safety through coordination of investigation, prevention, response, 
surveillance, applied research, health communication, and public 
policy; (14) provides program and administrative support for HICPAC; 
and (15) advises the Director, NCEZID, on policy matters concerning 
DHQP activities.
    Immunization Safety Office (CVLD12). (1) Assesses the safety of 
vaccines received by children, adolescents and adults; (2) 
coordinates vaccine safety activities at CDC; (3) monitors safety of 
new and currently available vaccines; (4) coordinates and maintains 
the Vaccine Adverse Event Reporting System and Vaccine Safety 
Datalink; (5) leads CDC' s scientific research to evaluate the 
safety of all currently available and new vaccines; and (6) works 
with other Federal agencies, State governments, and other public and 
private organizations to assess and promote the safety of vaccines.
    Division of High-Consequence Pathogens and Pathology (CVLE). The 
Division of High-Consequence Pathogens and Pathology (DHCPP) 
maximizes public health and safety nationally and internationally 
through the diagnosis, prevention, and control of disease, 
disability, and death caused by suspected and known viral, 
bacterial, prion, and related infections. In carrying out its 
mission, DHCPP: (1) Conducts surveillance, investigations, and 
studies of viral and bacterial diseases, including bioterrorism 
agents, as well as of transmissible spongiform encephalopathies, or 
prion diseases, and severe diseases of unknown, but suspected 
infectious etiology, to define their etiology and epidemiology, and 
to develop effective methods for diagnosis, treatment, control, and 
prevention; (2) conducts or participates in clinical, field, and 
laboratory research to develop, evaluate, and improve laboratory 
methods, materials, and therapeutic practices used for diagnosis, 
treatment, control, and prevention of viral, bacterial, and prion 
diseases, including bioterrorism agents; (3) conducts research on 
virus and bacterial transmission to develop effective control and 
prevention strategies and on vaccine effectiveness to assess 
prevention potential; (4) conducts laboratory, clinical, and 
epidemiologic studies of highly hazardous disease agents that 
require biosafety level 3 or biosafety level 4 security for their 
safe handling; (5) conducts ecological studies to develop and 
evaluate disease control and prevention measures; (6) provides 
epidemic aid, epidemiologic consultation, reference and diagnostic 
services, and technical assistance to State and local health 
departments, other Federal agencies, and national and international 
health organizations; (7) provides scientific and technical 
assistance to other CDC components when the work requires unique 
expertise or specialized equipment not available in other 
components; (8) provides routine and specialized laboratory training 
in the diagnosis, isolation, and characterization of viral and 
bacterial agents to personnel from State and local health 
departments and other national and international organizations; (9) 
provides training opportunities for EIS officers and others in CDC 
sponsored programs, including postgraduate students, postdoctoral 
fellows, and other public health and laboratory scientists; (10) 
provides expert pathological support for various infectious diseases 
to other groups at CDC, State and local health departments, other 
Office of Infectious Diseases (OID) components, and national and 
international organizations; and (11) serves as appropriately 
designated national and WHO Collaborating Centers for viral and 
bacterial diseases.
    Office of the Director (CVLE1). (1) Directs and manages the 
programs and activities of DHCPP; (2) provides leadership and 
guidance on policy, program planning and development, program 
management, and operations; (3) coordinates or assures coordination 
with the appropriate CDC, OID, and NCEZID offices on administrative 
and program matters; (4) reviews, prepares, and coordinates 
congressional testimony and briefing documents related to high-
consequence viral, bacterial, and prion diseases, and analyzes 
programmatic and policy implications of legislative proposals; (5) 
represents CDC, OID, and NCEZID programs and prevention policies in 
meetings with other governmental, private, and international 
organizations; (6) serves as CDC, OID, and NCEZID's primary internal 
and external communications contact regarding high consequence 
viral, bacterial, and prion disease issues; and (7) advises CDC, 
OID, and NCEZID on policy matters concerning DHCPP programs and 
activities.
    Prion and Public Health Office (CVLE12). (1) Serves as the lead 
Federal office for monitoring the occurrence of human prion disease 
in the U.S.; (2) conducts epidemiological investigations, studies, 
and multiple methods of surveillance to increase understanding of 
human prion diseases and selected diseases of unknown etiology 
(e.g., Kawasaki syndrome) for the purpose of informing disease 
control policies; (3) facilitates the study of brain autopsies by 
skilled pathologists of clinically diagnosed and suspected cases of 
human prion disease in the U.S. to enable early recognition of the 
emergence of any new prion disease (e.g., variant Creutzfeldt-Jacob 
Disease and possibly human chronic wasting disease); (4) provides 
prion disease consultations to clinicians, State and local health 
departments, other Federal agencies, and national and international 
organizations, including epidemic aid support as needed; (5) 
disseminates information and advice to the public on preventing or 
reducing the negative public impacts of prion diseases and selected 
diseases of unknown etiology; (6) serves as a DHCPP statistical 
analysis unit, collaborating with and supporting studies, 
investigations, and surveillance activities of epidemiologists and 
laboratory researchers; (7) provides statistical consultations and 
collaborates with researchers on local, national, and international 
public health morbidity and mortality studies that require expertise 
in manipulating and understanding large public health datasets; and 
(8) provides statistical and epidemiologic training opportunities 
for EIS officers and other personnel in CDC sponsored programs.
    One Health Office (CVLE13). (1) Serves as the agency focal point 
and provides the programmatic home for activities on One Health, an 
integrated approach to optimizing human and animal health that 
considers the interrelatedness among humans, animals, and their 
environments; (2) builds and organizes a portfolio of One Health 
activities, plans, and accomplishments and leads the efforts to 
promote and accomplish the activities through NCEZID and CDC 
programs and partnerships; (3) builds partnerships and facilitates 
collaboration both within and external to CDC; (4) manages and 
allocates NCEZID extra-budgetary resources from the Department of 
State/USAID, the Department of Defense/BTEP, the National Center for 
Environmental Health/Climate Change, and others, as appropriate; and 
(5) facilitates the exchange of information and enhances 
communication across disciplines by sponsoring visiting scientists 
and fellows, lectures, and meetings.
    Division of Preparedness and Emerging Infections (CVLG). The 
Division of Preparedness and Emerging Infections (DPEI) works to 
build and strengthen public health capacity by enhancing the ability 
of CDC and its public health partners to prepare for, prevent, and 
respond to infectious diseases, including outbreaks, bioterrorism, 
and other public health emergencies, through cross-cutting and 
specialized programs, technical expertise, and public health 
leadership. In carrying out these activities, the DPEI: (1) 
Advocates for CDC programs, health departments, and other partners 
on issues related to emerging infections, bioterrorism, and public 
health resources; (2) develops and implements infectious disease 
surveillance, laboratory, and capacity building activities in 
collaboration with other CDC programs and external partners; (3) 
works with infectious disease programs on processes for developing, 
awarding, managing, and evaluating infectious disease grants and 
cooperative agreements; (4) provides scientific and programmatic 
leadership, as well as management, administrative, and technical 
support for broad infectious disease cooperative agreements such as 
the Emerging Infections Program (EIPs) and the Epidemiology and 
Laboratory Capacity for Infectious Diseases (ELC) program; (5) 
collaborates across CDC and with national and international partners 
to address the scientific and response planning and preparedness 
issues for bioterrorism, emerging infections, and other infectious

[[Page 43193]]

disease emergencies; (6) provides the agency's initial rapid 
response capabilities (including 24 hour on-call emergency response 
coordination and epidemiologic and laboratory support) for 
bioterrorism and other infectious disease public health emergencies; 
(7) conducts, supports, and evaluates activities aimed at 
identifying and reducing risk factors for infectious diseases among 
residents of the Arctic and Subarctic regions; (8) maintains primary 
responsibility for development and management of the nation's 
Laboratory Response Network (LRN), including supporting the 
development, deployment, and quality control of diagnostic reagents 
for the LRN laboratories; (9) defines and promotes good laboratory 
practice standards, including providing consultation and training 
and improving communication and collaborations among public and 
private sector laboratories nationally and internationally; (10) 
serves as a primary screening laboratory for CDC for specimens that 
may contain threat agents; (11) analyzes the economic impact of 
infectious diseases in collaboration with other CDC infectious 
disease programs and collaborators outside the agency; (12) leads 
and coordinates infectious disease fellowships and training 
programs; (13) provides technical assistance and training on 
biosafety/biosecurity and bioterrorism agent detection and response 
to internal and external partners, including assistance with related 
public health and law enforcement investigations and planning for 
high profile national and international events; and (14) assists in 
medical countermeasures response and utilization coordination.
    Office of the Director (CVLG1). (1) Manages, directs, and 
coordinates the activities of DPEI; (2) provides leadership and 
guidance on division policy, program planning, program management, 
and operations; (3) provides division-wide administrative and 
program services and ensures coordination with the appropriate CIO 
or staff offices on administrative and program matters; (4) provides 
liaison with other governmental agencies, international 
organizations, academic institutions and other outside groups; (5) 
ensures coordination of cross-cutting division activities with 
appropriate NCEZID divisions, the Office of Public Health 
Preparedness and Response, the Office of Surveillance, Epidemiology, 
and Laboratory Services (OSELS), and other CDC CIOs and offices; and 
(6) advises the NCEZID Director, the Deputy Director for Infectious 
Diseases, and leadership in other CDC units on division policy 
matters.
    Division of Scientific Resources (CVLH). The Division of 
Scientific Resources (DSR) provides products, services, and 
specialized expertise to CDC staff and activities in support of 
research and service activities. In carrying out its mission, DSR: 
(1) Provides animals, laboratory supplies, animal and human blood 
products, glassware, mammalian tissue cultures, microbiological 
media, special reagents, and other laboratory materials in support 
of research and service activities to laboratories and investigators 
at CDC; (2) develops and implements applied research programs to 
expand and enhance the use of animal models necessary to support 
research and diagnostic programs and to improve breeding and 
husbandry procedures; (3) conducts applied research in cell biology 
and in the expansion of tissue culture technology as a research and 
diagnostic tool for infectious disease activities; (4) provides 
services for laboratory investigators in protein and DNA synthesis 
and sequencing, genomic sequencing, microarrays, proteomics, and 
molecular modeling; (5) maintains a bank of serum and other 
biological specimens of epidemiological and special significance to 
CDC's research and diagnostic activities; (6) obtains and 
distributes experimental and orphaned vaccines, drugs, antisera, 
antitoxins, and immune globulins; (7) manages and distributes the 
inventory, maintains the computerized system database, and provides 
general technical service support for the dispensing, lyophilizing, 
capping, and labeling of CDC reference reagents; (8) receives, 
triages, processes, and distributes specimens to CDC laboratories 
for reference diagnostic testing, research studies, and epidemics 
and reports diagnostic test results to submitting organizations; (9) 
manages all CDC exports and ensures compliance with regulations and 
serves as CDC liaison with Department of Commerce for export related 
issues; (10) produces and distributes specialized reagents and kits 
for the detection of select agents to members of the LRN; (11) 
provides services and expertise in development of quality systems to 
support compliance with the Food and Drug Administration regulations 
on production, distribution, and use of laboratory diagnostic 
reagents; (12) provides liaison activities, resources, and expertise 
for inquiries related to animals and zoonotic diseases; and (13) 
provides a centralized activity for tracking requests for and 
distributing select agents to investigators outside of CDC in 
compliance with Federal regulations.
    Office of the Director (CVLH1). (1) Manages, directs, and 
coordinates the activities of DSR; (2) provides leadership and 
guidance on policy, budget, program planning and development, 
program management, and operations; (3) provides DSR wide 
administrative and program services and coordinates or ensures 
coordination with the appropriate CIOs OID, and CDC staff offices on 
administrative and program matters; (4) provides liaison with other 
governmental agencies, international organizations, and other 
outside groups; (5) coordinates, in collaboration with the 
appropriate CIOs, OID, and CDC components, laboratory activities 
relating to support of outbreak investigations or laboratory-based 
research including but not limited to specimen management, 
biological reagents, and laboratory supplies; (6) maintains a 
formulary of investigational and licensed drugs and biologicals that 
are distributed to approved physicians for the prevention, control, 
and/or treatment of rare, tropical, or exceptional diseases; (7) 
collaborates with CDC and external partners on research related to 
STD transmitted infections as chronic infectious diseases; and (8) 
advises the Director, NCEZID, on policy matters concerning DSR 
activities.
    Division of Vector-Borne Diseases (CVLJ). (1) Conducts 
surveillance, investigations, and studies of vector-borne viral, 
rickettsial, and bacterial diseases to define disease etiology and 
to develop effective methods and strategies for diagnosis, 
prevention, and control; (2) conducts investigations on the biology, 
ecology, and control of arthropod vectors of viral, rickettsial, and 
bacterial diseases as a basis for development of new and/or 
modification of existing measures for more effective prevention and 
control; (3) conducts or participates in clinical, field, and 
laboratory studies to develop, evaluate, and improve laboratory 
methods, materials, and therapeutic practices used for diagnosis, 
prevention, and treatment of vector-borne infectious diseases; (4) 
provides epidemic aid and epidemiologic consultation, upon request, 
to State and local health departments, other Federal agencies, and 
national and international health organizations; (5) provides 
reference/diagnostic services for vector-borne viral, rickettsial, 
and bacterial diseases to State and local health departments, other 
Federal agencies, and national and international health 
organizations; (6) conducts research and collaborates on development 
and evaluation of vaccines; (7) provides scientific and technical 
assistance to other CDC components when the work requires unique 
expertise or specialized equipment not available in other 
components; (8) provides intramural and extramural technical 
expertise and assistance in professional training activities; and 
(9) serves as designated national and international reference 
centers for vector-borne viral, rickettsial, and bacterial diseases.
    Office of the Director (CVLJ1). (1) Directs and manages the 
programs and activities of the Division of Vector-Borne Diseases 
(DVBD); (2) provides leadership and guidance on policy, program 
planning and development, program management, and operations; (3) 
coordinates or assures coordination with the appropriate CDC, OID, 
and NCEZID offices on administrative and program matters; (4) 
reviews, prepares, and coordinates congressional testimony and 
briefing documents related to vector-borne infectious diseases, and 
analyzes programmatic and policy implications of legislative 
proposals; (5) represents CDC and NCEZID in meetings with other 
governmental, private, and international organizations; (6) serves 
as CDC and NCEZID's primary internal and external communications 
contact regarding vector-borne infectious disease issues; and (7) 
advises CDC and NCEZID on policy matters concerning DVBD programs 
and activities.

    Dated: July 9, 2010.
William P. Nichols,
Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2010-17794 Filed 7-22-10; 8:45 am]
BILLING CODE 4160-18-M